Background and Purpose: The effects of direct oral anticoagulants in nonvalvular atrial
fibrillation should be assessed in actual conditions of use. France has near-universal …

Background The introduction of non–vitamin K antagonist oral anticoagulants has been a
major advance for stroke prevention in atrial fibrillation; however, outcomes achieved in …

Background and Purpose—This ARISTOPHANES study (Anticoagulants for Reduction in
Stroke: Observational Pooled Analysis on Health Outcomes and Experience of Patients) …

Objective To compare effectiveness and safety of warfarin and the direct oral anticoagulants
(DOAC) dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation in routine …

Background Clinical trials have demonstrated that direct oral anticoagulants (DOACs) are at
least non-inferior to warfarin in reducing the risk of stroke/systemic embolism (SE) among …

Background There are no head-to-head randomized controlled trials comparing different
direct oral anticoagulants (DOACs). Thus, we systematically reviewed and meta-analyzed …

Background The comparative effectiveness and safety of individual direct oral
anticoagulants (DOACs) in clinical practice is largely unknown. The study objectives were to …

We performed a meta-analysis of data on the effectiveness and safety of apixaban
compared with other oral anticoagulants (warfarin or rivaroxaban or dabigatran or …

Background Stroke is the most serious clinical consequence of atrial fibrillation, which is the
most common cardiac arrhythmia. Non-vitamin K antagonist oral anticoagulants (NOACs) …

Background—Oral anticoagulants such as apixaban, dabigatran, and rivaroxaban are
alternatives to warfarin for preventing events in patients with atrial fibrillation. Direct …